Daytrana Delivers Customizable MPH Plasma Levels

MPH Levels Are a Result of Wear Time and Patch Size

Removable Daytrana^® delivers therapeutic MPH plasma levels for long- or shorter-acting control

• These data illustrate the unique feature of the patch, which stops administration of additional medication upon patch removal so that blood levels of medication can start to fall
• Transdermal administration of methylphenidate exhibits much less first-pass effect than oral administration to allow for a more efficient delivery of the medication
  • Consequently, a much lower dose of Daytrana on a mg/kg basis compared to oral dosages may still produce higher exposures of MPH with transdermal administration compared to oral administration

Drug concentration after multiple days of dosing

Lower limit of quantification (0.25 ng/mL).

Study 201: Drug concentration from multiple-dose administration of Daytrana in a randomized, double-blind, placebo controlled laboratory classroom study. Plasma samples were obtained for pharmacokinetic analysis at predose and 2, 3, 4.5, 6, 7.5, 9, 10.5, and 12 hours after dose administration.